{"gene":"PCSK1","run_date":"2026-04-29T11:37:58","timeline":{"discoveries":[{"year":1993,"finding":"PC1/3 is a calcium-dependent serine proteinase with optimal activity at pH 5.5–6.5 that undergoes autocatalytic cleavage of its N-terminal prosegment (at RSKR motif, residues 80–83) early in biosynthesis, and cleaves proenkephalin to yield peptide B-sized fragment; specificity studies show preference for arginine 4 amino acids N-terminal to the cleavage site.","method":"Purification of recombinant mouse PC1 from CHO conditioned medium, fluorogenic substrate assays, in vitro proenkephalin cleavage, inhibitor profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with purified recombinant enzyme, multiple orthogonal assays","pmids":["8449925"],"is_preprint":false},{"year":1994,"finding":"PC1/3 undergoes autocatalytic C-terminal truncation from 87 kDa to 74/66 kDa forms in vitro; the truncated forms have narrower pH optimum (5.0–5.5), are more enzymatically active but less stable, and show altered sensitivity to protease inhibitors compared with the 87-kDa form.","method":"In vitro spontaneous conversion assay, limited proteolysis, purification, fluorogenic substrate kinetics, inhibitor profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with multiple biochemical readouts","pmids":["8034588"],"is_preprint":false},{"year":1994,"finding":"Recombinant PC1 cleaves POMC in vitro at all paired-basic residue sites (except Lys-Arg and Lys-Lys in beta-lipotropin/beta-endorphin), generating ACTH intermediates, ACTH, joining peptide, 16-kDa N-POMC, N-POMC-(1-74), and beta-lipotropin, with a pH optimum of 6.0.","method":"In vitro processing of mouse POMC with partially purified recombinant rat PC1 from stably transfected L-cells, peptide product identification","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro reconstitution with defined substrate and product mapping","pmids":["8070378"],"is_preprint":false},{"year":1995,"finding":"The C-terminal truncation site of PC1 is at Arg590-Arg591; mutation of this site prevents processing from 87 kDa form, while a truncated mutant ending at this site is correctly routed to secretory granules and processes proneurotensin efficiently, indicating the C-terminal extension is not required for granule sorting but regulates enzyme activity.","method":"Site-directed mutagenesis of PC1 expressed in PC12 cells, proneurotensin processing assay, secretory pathway analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with defined substrate processing readout and subcellular localization","pmids":["7559585"],"is_preprint":false},{"year":1997,"finding":"The RRGDL motif in the P-domain of PC1 is critical for zymogen processing in the ER, C-terminal autocatalytic processing to the 66-kDa form in secretory granules, and proper trafficking to granules; RRGDL mutations cause ER retention/degradation, mis-sorting to the constitutive pathway, and impaired POMC processing.","method":"Site-directed mutagenesis (ARGDL, RAGDL, RRGEL variants), vaccinia-virus expression in BSC40/PC12/GH4C1 cells, pulse-chase analysis, immunocytochemistry, alpha1-PDX inhibitor co-expression","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with multiple cell-biological and biochemical assays","pmids":["9307023"],"is_preprint":false},{"year":1998,"finding":"PC1/SPC3 cleaves provasopressin at both vasopressin-neurophysin and neurophysin-glycopeptide junctions; cleavage specificity differs between the 86-kDa (unprocessed C-terminus) and 64-kDa (C-terminally truncated) forms: 86-kDa form cleaves only at the neurophysin-glycopeptide site, while 64-kDa forms cleave at both sites, demonstrating that the C-terminus alters cleavage specificity.","method":"In vitro processing of radiolabeled provasopressin and prooxytocin with different recombinant SPC3 forms, including 64-kDa SPC3-T truncation construct","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with multiple enzyme forms and defined substrates","pmids":["9523585"],"is_preprint":false},{"year":2003,"finding":"PC3/PC1 (86 and 64 kDa forms) associates with lipid rafts in secretory granule membranes; a 64-kDa form (PC3-TM) contains a transmembrane domain (residues 619–638) anchoring it to lipid rafts with an ~115-residue cytoplasmic tail; the transmembrane domain alone is sufficient to target a heterologous protein (IL2 receptor Tac ectodomain) to secretory granules.","method":"TX-100 detergent resistance, sucrose gradient flotation, cholesterol depletion, protease protection, immunolabeling, biotinylation of intact granules, 2D gel electrophoresis, IL2R-Tac chimera targeting assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical and cell-biological methods in single study","pmids":["12950171"],"is_preprint":false},{"year":2009,"finding":"The extreme C-terminal sorting domain of PC1/3 (residues 711–753) adopts two alpha-helices (722–728 and 738–750) by NMR; the second helix is necessary and sufficient to target a constitutively secreted protein to dense core secretory granules, and L745 anchors a hydrophobic patch critical for sorting; calcium binding by this helix promotes aggregation via the hydrophobic patch.","method":"NMR structure determination of PC1/3(711-753) in micelles, deletion/mutagenesis functional targeting assays, calcium-binding aggregation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — NMR structure combined with mutagenesis and functional targeting assays","pmids":["19376969"],"is_preprint":false},{"year":2007,"finding":"PC1/3, PC2, and PC5/6A are targeted to dense core secretory granules by a common mechanism requiring a C-terminal alpha-helix with clustered hydrophobic residues; predicted alpha-helix in PC5/6A C-terminus redirects a constitutively secreted protein to granules in AtT-20 cells.","method":"C-terminal fusion protein targeting assays in AtT-20 cells, alpha-helix prediction, comparison of PC1/3, PC2, PC5/6A sorting domains","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 2 — cell-based functional targeting assays with multiple PC family members","pmids":["17645548"],"is_preprint":false},{"year":1993,"finding":"PC1 (but not furin or PC2) efficiently cleaves prosomatostatin at the dibasic Arg-Lys site to produce somatostatin-14 in heterologous cell expression; furin mediates monobasic cleavage in the constitutive pathway, while PC1 is required for dibasic cleavage in the regulated pathway.","method":"Transient transfection of PC1, PC2 in COS-7 and AtT-20 cells; PSS processing product analysis; correlation with endogenous convertase expression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — heterologous expression with defined substrate and product characterization, multiple cell types","pmids":["8095501"],"is_preprint":false},{"year":1998,"finding":"Overexpression of PC1 in islet-derived InR1-G9 cells drives proglucagon processing toward glicentin, oxyntomodulin, and GLP-2 (intestinal-type products), but does not increase GLP-1(7-36NH2); antisense depletion of PC2 eliminates glicentin but does not alter glucagon, establishing distinct roles for PC1 and PC2 in proglucagon processing.","method":"Stable transfection of PC1 or antisense PC2 in InR1-G9 cells, HPLC and RIA of proglucagon-derived peptides","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — stable cell lines, multiple biochemical readouts, orthogonal gain- and loss-of-function","pmids":["9528943"],"is_preprint":false},{"year":2008,"finding":"The N221D variant of PC1/3 (encoded by rs6232) has significantly impaired catalytic activity in vitro; in N222D knock-in mice, the mutation causes obesity, abnormal proinsulin processing, reduced hypothalamic alpha-MSH, and impaired autocatalytic activation of mature PC1, phenocopying human PC1 deficiency.","method":"Functional analysis of N221D mutant in vitro; N222D mouse knock-in model with metabolic phenotyping, proinsulin processing assay","journal":"Nature genetics / Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro catalytic assay plus in vivo mouse model with multiple endocrine phenotypes","pmids":["18604207","16644867"],"is_preprint":false},{"year":2014,"finding":"The PC1/3 N222D mutation causes ER retention and accelerated proteasomal degradation of the mutant protein; coimmunoprecipitation shows N222D protein interacts with wild-type PC1/3 and exerts a modest dominant-negative effect on intracellular retention of WT enzyme.","method":"Pulse-chase immunoprecipitation, metabolic labeling, immunohistochemistry, ubiquitin-proteasome inhibitor experiments, co-IP in transfected cells","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal cell-biology methods with mechanistic follow-up","pmids":["24828610"],"is_preprint":false},{"year":2015,"finding":"ER-retained PC1/3 mutants (G209R and G593R) induce ER stress markers and exert dominant-negative blockade of wild-type PC1/3 prodomain cleavage and expression, facilitating entry of WT protein into a proteasomal degradation pathway.","method":"Expression of mutants alongside WT PC1/3 in transfected cells, ER stress marker assays, Western blot analysis of WT PC1/3 processing","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — cell-based co-expression with multiple biochemical readouts","pmids":["26207343"],"is_preprint":false},{"year":2011,"finding":"PC1/3 exists as multiple ionic forms including inactive aggregates and stable oligomers; the most active form is a probable homodimer of 87-kDa PC1/3; enzyme activity of 87-kDa oligomers exhibits partial latency that is relieved by dilution or by preincubation with fluorogenic substrate or peptides containing paired basic residues, suggesting regulation by self-interaction and substrate binding.","method":"Ion exchange chromatography, 2D gel electrophoresis, gel filtration, cross-linking, fluorogenic activity assays with and without substrate peptides","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biophysical and enzymatic methods","pmids":["21303942"],"is_preprint":false},{"year":2001,"finding":"proSAAS (encoded by Pcsk1n) is a potent and specific inhibitor of PC1/3 (SPC3) and is co-expressed with SPC3 in nearly all neuroendocrine cells and neurons throughout the brain and peripheral endocrine tissues, supporting an in vivo inhibitory role.","method":"In situ hybridization histochemistry double-labeling in rat CNS and peripheral tissues; correlation with prior in vitro inhibition data","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 3 — co-localization study supporting in vitro inhibition data from prior work","pmids":["11517193"],"is_preprint":false},{"year":2012,"finding":"Pax6 transcription factor directly binds the Pcsk1n (proSAAS) promoter and down-regulates its expression; Pax6 deficiency elevates proSAAS levels, which inhibits PC1/3 C-terminal cleavage and reduces PC1/3 activity, thereby impairing proinsulin processing.","method":"Luciferase reporter assay, chromatin immunoprecipitation, EMSA, Pcsk1n RNAi in MIN6 cells, PC1/3 activity assay, proinsulin processing assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including ChIP, EMSA, reporter, functional rescue","pmids":["23056534"],"is_preprint":false},{"year":2001,"finding":"Thyroid hormone receptor alpha1 (TRalpha1) negatively regulates PC1 promoter activity by binding to novel TRE-like sequences located at −10 to +19 bp relative to the transcription start site, both as monomer/homodimer and as TRalpha1/RXRbeta heterodimer/multimer.","method":"5' deletion constructs of hPC1 promoter transfected into GH3 cells, EMSA with purified TRalpha1 and RXRbeta, point mutations of putative TREs","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1-2 — promoter deletion analysis, purified protein EMSA, mutagenesis","pmids":["11120670"],"is_preprint":false},{"year":2020,"finding":"Transcription factor Creb3l1 directly binds a G-box motif in the Pcsk1 promoter and transcriptionally activates PC1/3 expression; viral Creb3l1 over-expression in hypothalamic supraoptic nuclei increases Pcsk1, while knockdown reduces it; in AtT20 cells, Creb3l1 knockdown reduces Pcsk1 expression.","method":"RNA-seq of Creb3l1 KD AtT20 cells, promoter-binding assay, viral vector over-expression/knockdown in vivo and in vitro","journal":"Journal of neuroendocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple gain- and loss-of-function approaches with direct promoter binding evidence","pmids":["32319174"],"is_preprint":false},{"year":1995,"finding":"Recombinant PC1 cleaves anthrax toxin protective antigen (PA83) at the tetrabasic RKKR167 site to generate PA63 and PA20, with pH optimum 6.0 and calcium dependence; PC1 prefers substrates with basic residues at −1 and −4 positions; bovine intermediate lobe secretory vesicle membrane PC1 (immunodepleted) also cleaves PA, confirming in vivo relevance.","method":"In vitro cleavage of PA with recombinant PC1 from L-cells, N-terminal sequencing of products, site-directed mutagenesis of PA cleavage site, immunodepletion with PC1/PC2 antisera, cellular toxicity assay","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with N-terminal sequencing and mutagenesis of substrate","pmids":["7840657"],"is_preprint":false},{"year":2016,"finding":"In macrophages, PC1/3 inhibition (knockdown or genetic KO) promotes an M1 pro-inflammatory phenotype characterized by filopodial extensions, TLR4 MyD88-dependent signaling, increased calcium entry, and secretion of pro-inflammatory factors recruiting cytotoxic T cells.","method":"PC1/3 siRNA knockdown in NR8383 macrophages, validation in PC1/3-deficient mouse macrophages, proteomic analysis of secretomes and intracellular proteins","journal":"Molecular & cellular proteomics : MCP","confidence":"Medium","confidence_rationale":"Tier 2 — two model systems (cell and mouse KO) with proteomics, but mechanistic depth limited","pmids":["26330543"],"is_preprint":false},{"year":2016,"finding":"PC1/3 co-localizes with and controls TLR9 trafficking in macrophages; PC1/3 knockdown causes TLR9 clustering in multivesicular bodies (Rab7+), dampens anti-inflammatory STAT3 signaling, and promotes pro-inflammatory NF-kB signaling and cytokine secretion.","method":"PC1/3 knockdown in NR8383 macrophages and PC1/3 KO mice macrophages, co-localization imaging with TLR9/Rab7 markers, STAT3/NF-kB pathway readouts, cytokine ELISA","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — two model systems with defined pathway readouts; co-localization supports mechanistic interpretation","pmids":["26778167"],"is_preprint":false},{"year":2014,"finding":"A heterozygous nonsense PCSK1 mutation (p.Arg80*) produces a truncated propeptide fragment that inhibits PCSK1 enzyme activity in vitro; this inhibition does not involve strong physical interaction with the mature enzyme, yet is sufficient to cause dominantly inherited obesity in a three-generation family.","method":"In vitro functional analysis of truncated propeptide, co-segregation analysis in family, activity assays","journal":"International journal of obesity","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro enzyme inhibition assay with genetic co-segregation support","pmids":["24890885"],"is_preprint":false},{"year":2016,"finding":"In Prader-Willi syndrome, loss of SNORD116 leads to reduced NHLH2 and PC1/3 (PCSK1) expression in iPSC-derived neurons and mouse hypothalamus; Snord116 paternal KO mice show in vivo defects in prohormone processing of proinsulin, pro-GHRH, and proghrelin, establishing PC1/3 as the mechanistic link between SNORD116 deficiency and PWS endocrinopathy.","method":"iPSC-derived neurons from PWS patients, Snord116p-/m+ mice, in vivo prohormone processing assays (proinsulin, pro-GHRH, proghrelin), PC1/3 protein quantification in islet/hypothalamus/stomach","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — human iPSC-derived neurons plus mouse model with direct prohormone processing readouts","pmids":["27941249"],"is_preprint":false},{"year":2021,"finding":"GLP-1 receptor agonist liraglutide increases PC1/3 (PCSK1) mRNA expression in a subset of pancreatic alpha cells in a beta-cell GLP-1R-dependent manner in mice, promoting a beta-cell-like gene expression signature and increased bihormonal insulin+glucagon+ cells.","method":"Mouse GLP-1R beta-cell-specific KO models, human islet scRNA-seq (DART-Seq), IHC for bihormonal cells","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — genetic mouse model plus human islet validation, but mechanism upstream of PC1/3 induction is indirect","pmids":["33554958"],"is_preprint":false},{"year":2017,"finding":"CRISPR-Cas9 and shRNA-mediated PCSK1 deficiency in hESC-derived hypothalamic neurons results in increased unprocessed POMC, decreased ratios of processed POMC peptides (ACTH, alpha-MSH), increased melanocortin receptor expression, increased PRCP expression, and reduced ACTH secretion, phenocopying PC1/3-null mice and human patients.","method":"CRISPR-Cas9 KO and shRNA KD of PCSK1 in hESC-derived hypothalamic neurons, POMC peptide processing analysis","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 — two independent KO/KD approaches in human-derived neurons with defined molecular phenotype","pmids":["28132887"],"is_preprint":false}],"current_model":"PCSK1-encoded prohormone convertase 1/3 (PC1/3) is a calcium-dependent serine endoprotease of the subtilisin family that undergoes autocatalytic propeptide removal in the ER and C-terminal truncation in secretory granules to generate progressively more active forms (87→74/66 kDa); it cleaves prohormone substrates (POMC, proinsulin, proglucagon, proenkephalin, prosomatostatin, provasopressin, proghrelin, pro-GHRH) at paired basic residues with pH optimum ~5.5–6.5; targeting to dense core secretory granules is mediated by a C-terminal alpha-helical sorting domain (residues 738–750) containing a critical hydrophobic patch centered on L745 that binds calcium and promotes membrane aggregation; enzyme activity is regulated by self-oligomerization, substrate-induced stabilization, the endogenous inhibitor proSAAS/PCSK1N, and transcriptional control by thyroid hormone receptors and Creb3l1; ER-retained missense mutants cause dominant-negative suppression of wild-type PC1/3 maturation and activate the unfolded protein response, while obesity-associated variants (N221D) cause ER retention and proteasomal degradation with consequent impairment of prohormone processing; in macrophages, PC1/3 additionally controls TLR9 endosomal trafficking and inflammatory signaling."},"narrative":{"teleology":[{"year":1993,"claim":"Establishing PC1/3 as a calcium-dependent, acidic-pH-optimum endoprotease with paired-basic-residue specificity resolved how prohormones are cleaved within the regulated secretory pathway.","evidence":"Purification of recombinant mouse PC1 from CHO cells with fluorogenic substrate kinetics, proenkephalin cleavage, and inhibitor profiling; parallel cell-based prosomatostatin processing assays","pmids":["8449925","8095501"],"confidence":"High","gaps":["Crystal structure of the catalytic domain not yet determined","Full kinetic parameters for diverse prohormone substrates not systematically measured"]},{"year":1994,"claim":"Demonstrating that PC1/3 undergoes autocatalytic C-terminal truncation generating 74/66-kDa forms with higher activity and narrower pH optima revealed a built-in activation cascade that tunes enzyme function along the secretory pathway.","evidence":"In vitro spontaneous conversion assays, kinetics of multiple PC1 forms, and in vitro POMC processing with product mapping","pmids":["8034588","8070378"],"confidence":"High","gaps":["Cellular compartment where each truncation step occurs was inferred but not directly visualized","Structural basis for activity change upon truncation unknown"]},{"year":1995,"claim":"Mapping the C-terminal truncation site to Arg590–Arg591 and showing that a truncated construct still sorts to secretory granules separated the enzyme-activation role of the C-terminus from its granule-targeting function.","evidence":"Site-directed mutagenesis in PC12 cells with proneurotensin processing and subcellular localization readouts","pmids":["7559585"],"confidence":"High","gaps":["Sorting determinant downstream of residue 591 not yet mapped","Protease responsible for C-terminal cleavage in vivo not identified"]},{"year":1997,"claim":"Identifying the P-domain RRGDL motif as essential for ER zymogen processing, granule-compartment truncation, and correct trafficking established a single structural element governing multiple maturation checkpoints.","evidence":"Mutagenesis of RRGDL in BSC40/PC12/GH4C1 cells with pulse-chase, immunocytochemistry, and POMC processing assays","pmids":["9307023"],"confidence":"High","gaps":["Structural role of RRGDL in folding versus direct sorting interaction not resolved","Whether P-domain mutations affect calcium binding was not tested"]},{"year":1998,"claim":"Showing that the 86-kDa and 64-kDa PC1/3 forms have different cleavage-site preferences on provasopressin demonstrated that C-terminal truncation is not merely activating but also specificity-altering, explaining tissue-specific prohormone processing patterns.","evidence":"In vitro processing of radiolabeled provasopressin with defined recombinant SPC3 forms","pmids":["9523585"],"confidence":"High","gaps":["Mechanism by which C-terminal domain allosterically restricts cleavage-site selection unknown"]},{"year":1998,"claim":"Demonstrating that PC1 overexpression drives intestinal-type proglucagon processing (glicentin, oxyntomodulin, GLP-2) while PC2 generates glucagon resolved the long-standing question of how tissue-specific proglucagon products arise from differential convertase expression.","evidence":"Stable PC1 transfection and antisense PC2 depletion in InR1-G9 cells with HPLC/RIA product analysis","pmids":["9528943"],"confidence":"High","gaps":["GLP-1(7-36NH2) was not increased by PC1 alone, implying additional processing steps or enzymes"]},{"year":2001,"claim":"Identification of proSAAS as a potent endogenous PC1/3 inhibitor co-expressed in neuroendocrine tissues established a physiological feedback mechanism for controlling convertase activity in vivo.","evidence":"In situ hybridization double-labeling of proSAAS and SPC3 throughout rat CNS and endocrine tissues","pmids":["11517193"],"confidence":"Medium","gaps":["Direct in vivo demonstration that proSAAS regulates PC1/3 activity (e.g., proSAAS KO phenotype) was not shown in this study","Stoichiometry and kinetics of inhibition in granule lumen not measured"]},{"year":2001,"claim":"Demonstrating that thyroid hormone receptor α1 directly represses the PCSK1 promoter via novel TRE-like elements revealed a hormonal transcriptional control layer for PC1/3 expression.","evidence":"Promoter-deletion and EMSA with purified TRα1/RXRβ in GH3 cells","pmids":["11120670"],"confidence":"High","gaps":["In vivo thyroid hormone regulation of PC1/3 protein levels and prohormone processing not demonstrated"]},{"year":2003,"claim":"Discovery that a 64-kDa PC1/3 form contains a transmembrane domain (residues 619–638) anchoring it to lipid rafts in secretory granule membranes, sufficient for granule targeting of a heterologous protein, revealed an unexpected membrane-tethered convertase population.","evidence":"Detergent resistance, sucrose gradient flotation, protease protection, IL2R-Tac chimera targeting assay","pmids":["12950171"],"confidence":"High","gaps":["Whether the transmembrane form represents a physiologically significant fraction of total PC1/3 in vivo is unclear","Relationship between transmembrane and soluble C-terminally truncated forms not fully resolved"]},{"year":2009,"claim":"NMR structure of the C-terminal sorting domain (residues 711–753) pinpointed a second α-helix (738–750) with a hydrophobic patch centered on L745 as the necessary and sufficient granule-sorting signal, with calcium-dependent aggregation as the targeting mechanism.","evidence":"NMR in micelles, deletion/point mutagenesis targeting assays, calcium-binding aggregation assay","pmids":["19376969"],"confidence":"High","gaps":["Membrane receptor or lipid species mediating initial helix–granule interaction not identified","Sorting mechanism shared with PC2/PC5 helix not structurally compared"]},{"year":2008,"claim":"Linking the common obesity-associated N221D variant to impaired catalytic activity in vitro and demonstrating that N222D knock-in mice phenocopy human PC1/3 deficiency (obesity, abnormal proinsulin processing, reduced α-MSH) provided the first direct genetic evidence that partial PC1/3 loss causes metabolic disease.","evidence":"In vitro catalytic assays of N221D; N222D knock-in mouse metabolic phenotyping and proinsulin processing","pmids":["18604207","16644867"],"confidence":"High","gaps":["Whether the variant affects folding, ER exit, or catalysis per se was not fully dissected at this stage"]},{"year":2011,"claim":"Demonstrating that 87-kDa PC1/3 forms latent oligomers whose activity is relieved by dilution or substrate peptides uncovered a self-regulatory mechanism whereby enzyme concentration and substrate availability gate convertase output.","evidence":"Ion exchange chromatography, gel filtration, cross-linking, and fluorogenic activity assays with substrate peptides","pmids":["21303942"],"confidence":"High","gaps":["Oligomer interface not structurally mapped","In vivo relevance of concentration-dependent latency not tested"]},{"year":2014,"claim":"Showing that the N222D mutant undergoes ER retention and proteasomal degradation and exerts a dominant-negative effect on wild-type PC1/3 maturation via co-immunoprecipitable interaction explained how heterozygous missense variants cause haploinsufficiency-exceeding disease severity.","evidence":"Pulse-chase, metabolic labeling, proteasome-inhibitor rescue, co-IP in transfected cells","pmids":["24828610"],"confidence":"High","gaps":["Whether ER-associated degradation is ERAD-L or ERAD-C pathway not specified","Chaperone partners mediating retention not identified"]},{"year":2014,"claim":"A heterozygous nonsense mutation (p.Arg80*) producing a truncated propeptide that inhibits PC1/3 in trans established propeptide-mediated dominant-negative inhibition as a distinct pathogenic mechanism for monogenic obesity.","evidence":"In vitro inhibition assays of truncated propeptide; co-segregation in a three-generation family","pmids":["24890885"],"confidence":"Medium","gaps":["Physical interaction between truncated propeptide and mature enzyme was not detected, leaving mechanism of inhibition unclear","Only one family studied"]},{"year":2015,"claim":"Demonstrating that additional ER-retained PC1/3 mutants (G209R, G593R) induce the unfolded protein response and block wild-type prodomain cleavage generalized the dominant-negative/ER-stress mechanism beyond N221D to a class of pathogenic variants.","evidence":"Co-expression of mutant and WT PC1/3 with ER stress marker assays and Western blot","pmids":["26207343"],"confidence":"High","gaps":["Whether UPR activation contributes to disease phenotype beyond PC1/3 loss was not tested"]},{"year":2016,"claim":"Establishing that SNORD116 loss reduces NHLH2 and PC1/3 expression in iPSC-derived neurons and that Snord116-KO mice have defective prohormone processing identified PC1/3 deficiency as the mechanistic bridge between SNORD116 deletion and Prader–Willi syndrome endocrinopathy.","evidence":"PWS patient iPSC-derived neurons, Snord116p−/m+ mice, in vivo prohormone processing of proinsulin/pro-GHRH/proghrelin","pmids":["27941249"],"confidence":"High","gaps":["Direct mechanism by which SNORD116 snoRNA regulates NHLH2/PCSK1 mRNA (splicing, stability, translation) not elucidated"]},{"year":2016,"claim":"Revealing that PC1/3 controls TLR9 endosomal trafficking and inflammatory polarization in macrophages expanded the enzyme's role beyond neuroendocrine prohormone processing to innate immune regulation.","evidence":"PC1/3 knockdown in NR8383 macrophages and KO mouse macrophages with TLR9/Rab7 co-localization, STAT3/NF-κB pathway readouts, secretome proteomics","pmids":["26778167","26330543"],"confidence":"Medium","gaps":["PC1/3 substrate in macrophages that mediates TLR9 trafficking not identified","Whether catalytic activity or a non-enzymatic function is required was not determined"]},{"year":2017,"claim":"CRISPR and shRNA ablation of PCSK1 in human ESC-derived hypothalamic neurons recapitulated impaired POMC processing with reduced ACTH/α-MSH secretion, validating the enzyme's non-redundant role in a human neuronal context.","evidence":"PCSK1 KO/KD in hESC-derived hypothalamic neurons with POMC peptide quantification","pmids":["28132887"],"confidence":"High","gaps":["Compensation by other convertases (PC2, furin) in human neurons not systematically assessed"]},{"year":2020,"claim":"Identification of Creb3l1 as a direct transcriptional activator binding the Pcsk1 promoter G-box added a second transcription factor (beyond TRα1) to the regulatory circuit controlling PC1/3 expression in hypothalamic neurons.","evidence":"RNA-seq, promoter-binding assay, viral Creb3l1 overexpression/knockdown in vivo (supraoptic nucleus) and in AtT20 cells","pmids":["32319174"],"confidence":"High","gaps":["Physiological stimuli that activate Creb3l1 upstream of Pcsk1 not defined","Whether Creb3l1 regulation extends beyond hypothalamic neurons not tested"]},{"year":null,"claim":"Major unresolved questions include the structural basis for substrate selectivity and C-terminal allosteric regulation, the identity of PC1/3 substrates in macrophages and other non-neuroendocrine cells, the mechanism by which SNORD116 controls PCSK1 expression, and whether dominant-negative ER-stress effects of pathogenic variants contribute to disease beyond simple loss of enzyme activity.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution full-length structure of PC1/3","Macrophage substrate identity unknown","SNORD116–PCSK1 regulatory mechanism undefined","In vivo contribution of UPR activation to disease pathogenesis untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2,3,5,9,10,11,14,19,22,25]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,19]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[3,6,7,8]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[4,12,13]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[21]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,2,3,5,9,10,11,25]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[6,7,8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[20,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[20,21]}],"complexes":[],"partners":["PCSK1N","POMC","TLR9","CREB3L1","PAX6","THRA"],"other_free_text":[]},"mechanistic_narrative":"PCSK1 encodes prohormone convertase 1/3 (PC1/3), a calcium-dependent subtilisin-like serine endoprotease that is the principal processing enzyme for neuroendocrine prohormones in the regulated secretory pathway. PC1/3 undergoes sequential autocatalytic activation—N-terminal propeptide removal in the ER followed by C-terminal truncation (87→74→66 kDa) in secretory granules—yielding progressively more active forms with shifted pH optima and altered substrate specificity, and cleaves proinsulin, POMC, proglucagon, prosomatostatin, provasopressin, proghrelin, and pro-GHRH at paired basic residues [PMID:8449925, PMID:8034588, PMID:8070378, PMID:9528943, PMID:27941249]. Targeting to dense-core secretory granules depends on a C-terminal α-helical sorting domain (residues 738–750) whose hydrophobic patch (centered on L745) promotes calcium-dependent membrane aggregation, while enzyme activity is further regulated by homodimerization, substrate-induced delatentization, and the endogenous inhibitor proSAAS [PMID:19376969, PMID:21303942, PMID:11517193]. Loss-of-function and dominant-negative PCSK1 mutations—including ER-retained missense variants that activate the unfolded protein response and recruit wild-type PC1/3 into proteasomal degradation—cause monogenic obesity with impaired prohormone processing, and reduced PCSK1 expression downstream of SNORD116 loss mechanistically links Prader–Willi syndrome to its characteristic endocrinopathy [PMID:18604207, PMID:24828610, PMID:26207343, PMID:24890885, PMID:27941249]."},"prefetch_data":{"uniprot":{"accession":"P29120","full_name":"Neuroendocrine convertase 1","aliases":["Prohormone convertase 1","Proprotein convertase 1","PC1"],"length_aa":753,"mass_kda":84.2,"function":"Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin, insulin and AGRP","subcellular_location":"Cytoplasmic vesicle, secretory vesicle","url":"https://www.uniprot.org/uniprotkb/P29120/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PCSK1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PCSK1","total_profiled":1310},"omim":[{"mim_id":"612362","title":"BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 12; BMIQ12","url":"https://www.omim.org/entry/612362"},{"mim_id":"607353","title":"RHO-RELATED BTB DOMAIN-CONTAINING PROTEIN 3; RHOBTB3","url":"https://www.omim.org/entry/607353"},{"mim_id":"606641","title":"BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 1; BMIQ1","url":"https://www.omim.org/entry/606641"},{"mim_id":"603462","title":"CELL DIVISION CYCLE 23; CDC23","url":"https://www.omim.org/entry/603462"},{"mim_id":"601665","title":"OBESITY","url":"https://www.omim.org/entry/601665"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":31.0},{"tissue":"pituitary gland","ntpm":11.4}],"url":"https://www.proteinatlas.org/search/PCSK1"},"hgnc":{"alias_symbol":["PC1","PC3","SPC3","PC1/3"],"prev_symbol":["NEC1"]},"alphafold":{"accession":"P29120","domains":[{"cath_id":"3.30.70.850","chopping":"31-105","consensus_level":"high","plddt":93.5801,"start":31,"end":105},{"cath_id":"3.40.50.200","chopping":"148-455","consensus_level":"high","plddt":96.5924,"start":148,"end":455},{"cath_id":"2.60.120.260","chopping":"466-606","consensus_level":"high","plddt":95.8922,"start":466,"end":606}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29120","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29120-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29120-F1-predicted_aligned_error_v6.png","plddt_mean":82.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PCSK1","jax_strain_url":"https://www.jax.org/strain/search?query=PCSK1"},"sequence":{"accession":"P29120","fasta_url":"https://rest.uniprot.org/uniprotkb/P29120.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29120/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29120"}},"corpus_meta":[{"pmid":"21432867","id":"PMC_21432867","title":"PC3 is a cell line characteristic of prostatic small cell carcinoma.","date":"2011","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/21432867","citation_count":375,"is_preprint":false},{"pmid":"1316544","id":"PMC_1316544","title":"Distribution and regulation of the prohormone convertases PC1 and PC2 in the rat pituitary.","date":"1992","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/1316544","citation_count":261,"is_preprint":false},{"pmid":"18604207","id":"PMC_18604207","title":"Common nonsynonymous variants in PCSK1 confer risk of obesity.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18604207","citation_count":225,"is_preprint":false},{"pmid":"11377414","id":"PMC_11377414","title":"In search of a function for the TIS21/PC3/BTG1/TOB family.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11377414","citation_count":216,"is_preprint":false},{"pmid":"27861127","id":"PMC_27861127","title":"Nec-1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice.","date":"2017","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27861127","citation_count":130,"is_preprint":false},{"pmid":"8046441","id":"PMC_8046441","title":"The developmental expression in rat of proteases furin, PC1, PC2, and carboxypeptidase E: implications for early maturation of proteolytic processing capacity.","date":"1994","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8046441","citation_count":125,"is_preprint":false},{"pmid":"1404596","id":"PMC_1404596","title":"Mammalian subtilisin-related proteinases in cleavage activation of the paramyxovirus fusion glycoprotein: superiority of furin/PACE to PC2 or PC1/PC3.","date":"1992","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/1404596","citation_count":120,"is_preprint":false},{"pmid":"8449925","id":"PMC_8449925","title":"Purification and characterization of the prohormone convertase PC1(PC3).","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8449925","citation_count":116,"is_preprint":false},{"pmid":"27187081","id":"PMC_27187081","title":"PCSK1 Mutations and Human Endocrinopathies: From Obesity to Gastrointestinal Disorders.","date":"2016","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27187081","citation_count":114,"is_preprint":false},{"pmid":"27941249","id":"PMC_27941249","title":"Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27941249","citation_count":113,"is_preprint":false},{"pmid":"16644867","id":"PMC_16644867","title":"Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16644867","citation_count":111,"is_preprint":false},{"pmid":"10506829","id":"PMC_10506829","title":"The cell biology of the prohormone convertases PC1 and PC2.","date":"1999","source":"Progress in nucleic acid research and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10506829","citation_count":110,"is_preprint":false},{"pmid":"10816641","id":"PMC_10816641","title":"The subtilisin/kexin family of precursor convertases. Emphasis on PC1, PC2/7B2, POMC and the novel enzyme SKI-1.","date":"1999","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10816641","citation_count":108,"is_preprint":false},{"pmid":"23966032","id":"PMC_23966032","title":"The anticancer effect of fucoidan in PC-3 prostate cancer cells.","date":"2013","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/23966032","citation_count":91,"is_preprint":false},{"pmid":"8034588","id":"PMC_8034588","title":"Enzymatic properties of carboxyl-terminally truncated prohormone convertase 1 (PC1/SPC3) and evidence for autocatalytic conversion.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8034588","citation_count":89,"is_preprint":false},{"pmid":"27288825","id":"PMC_27288825","title":"PCSK1 Variants and Human Obesity.","date":"2016","source":"Progress in molecular biology and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/27288825","citation_count":85,"is_preprint":false},{"pmid":"7925129","id":"PMC_7925129","title":"Developmental expression of the prohormone convertases PC1 and PC2 in mouse pancreatic islets.","date":"1994","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7925129","citation_count":81,"is_preprint":false},{"pmid":"8095501","id":"PMC_8095501","title":"Heterologous processing of prosomatostatin in constitutive and regulated secretory pathways. Putative role of the endoproteases furin, PC1, and PC2.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8095501","citation_count":79,"is_preprint":false},{"pmid":"19509250","id":"PMC_19509250","title":"Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin.","date":"2009","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19509250","citation_count":77,"is_preprint":false},{"pmid":"15056715","id":"PMC_15056715","title":"Dual control of neurogenesis by PC3 through cell cycle inhibition and induction of Math1.","date":"2004","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15056715","citation_count":75,"is_preprint":false},{"pmid":"11135107","id":"PMC_11135107","title":"NEC1, a novel gene, highly expressed in nectary tissue of Petunia hybrida.","date":"2000","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11135107","citation_count":72,"is_preprint":false},{"pmid":"9186547","id":"PMC_9186547","title":"Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.","date":"1996","source":"Invasion & metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/9186547","citation_count":64,"is_preprint":false},{"pmid":"12360398","id":"PMC_12360398","title":"BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12360398","citation_count":64,"is_preprint":false},{"pmid":"17875778","id":"PMC_17875778","title":"Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17875778","citation_count":63,"is_preprint":false},{"pmid":"9768513","id":"PMC_9768513","title":"nec1, a gene conferring a necrogenic phenotype, is conserved in plant-pathogenic Streptomyces spp. and linked to a transposase pseudogene.","date":"1998","source":"Molecular plant-microbe interactions : MPMI","url":"https://pubmed.ncbi.nlm.nih.gov/9768513","citation_count":60,"is_preprint":false},{"pmid":"17371797","id":"PMC_17371797","title":"Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3.","date":"2007","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17371797","citation_count":59,"is_preprint":false},{"pmid":"11749777","id":"PMC_11749777","title":"Effect of scopoletin on PC3 cell proliferation and apoptosis.","date":"2001","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/11749777","citation_count":55,"is_preprint":false},{"pmid":"11823214","id":"PMC_11823214","title":"Horizontal transfer of the plant virulence gene, nec1, and flanking sequences among genetically distinct Streptomyces strains in the Diastatochromogenes cluster.","date":"2002","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11823214","citation_count":54,"is_preprint":false},{"pmid":"19528091","id":"PMC_19528091","title":"Association of variants in the PCSK1 gene with obesity in the EPIC-Norfolk study.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19528091","citation_count":54,"is_preprint":false},{"pmid":"24890885","id":"PMC_24890885","title":"A nonsense loss-of-function mutation in PCSK1 contributes to dominantly inherited human obesity.","date":"2014","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/24890885","citation_count":53,"is_preprint":false},{"pmid":"8961929","id":"PMC_8961929","title":"SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.","date":"1996","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8961929","citation_count":53,"is_preprint":false},{"pmid":"1765368","id":"PMC_1765368","title":"Chromosomal assignments of the genes for neuroendocrine convertase PC1 (NEC1) to human 5q15-21, neuroendocrine convertase PC2 (NEC2) to human 20p11.1-11.2, and furin (mouse 7[D1-E2] region).","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1765368","citation_count":49,"is_preprint":false},{"pmid":"1605851","id":"PMC_1605851","title":"The cDNA sequence of the human pro-hormone and pro-protein convertase PC1.","date":"1992","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1605851","citation_count":49,"is_preprint":false},{"pmid":"16341885","id":"PMC_16341885","title":"Barley necrotic locus nec1 encodes the cyclic nucleotide-gated ion channel 4 homologous to the Arabidopsis HLM1.","date":"2005","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/16341885","citation_count":47,"is_preprint":false},{"pmid":"33554958","id":"PMC_33554958","title":"GLP-1 receptor signaling increases PCSK1 and β cell features in human α cells.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33554958","citation_count":47,"is_preprint":false},{"pmid":"35528826","id":"PMC_35528826","title":"Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.","date":"2022","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/35528826","citation_count":46,"is_preprint":false},{"pmid":"21437630","id":"PMC_21437630","title":"Association of type 2 diabetes susceptibility genes (TCF7L2, SLC30A8, PCSK1 and PCSK2) and proinsulin conversion in a Chinese population.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21437630","citation_count":46,"is_preprint":false},{"pmid":"20534142","id":"PMC_20534142","title":"Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion.","date":"2010","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20534142","citation_count":46,"is_preprint":false},{"pmid":"26762158","id":"PMC_26762158","title":"60 YEARS OF POMC: From the prohormone theory to pro-opiomelanocortin and to proprotein convertases (PCSK1 to PCSK9).","date":"2016","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26762158","citation_count":43,"is_preprint":false},{"pmid":"25355447","id":"PMC_25355447","title":"The association of common variants in PCSK1 with obesity: a HuGE review and meta-analysis.","date":"2014","source":"American journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/25355447","citation_count":42,"is_preprint":false},{"pmid":"31852976","id":"PMC_31852976","title":"PPIP5K2 and PCSK1 are Candidate Genetic Contributors to Familial Keratoconus.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31852976","citation_count":42,"is_preprint":false},{"pmid":"22792402","id":"PMC_22792402","title":"Selection signature analysis implicates the PC1/PCSK1 region for chicken abdominal fat content.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22792402","citation_count":42,"is_preprint":false},{"pmid":"17555268","id":"PMC_17555268","title":"Streptomyces turgidiscabies secretes a novel virulence protein, Nec1, which facilitates infection.","date":"2007","source":"Molecular plant-microbe interactions : MPMI","url":"https://pubmed.ncbi.nlm.nih.gov/17555268","citation_count":41,"is_preprint":false},{"pmid":"12950171","id":"PMC_12950171","title":"The prohormone processing enzyme PC3 is a lipid raft-associated transmembrane protein.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12950171","citation_count":41,"is_preprint":false},{"pmid":"9307023","id":"PMC_9307023","title":"The integrity of the RRGDL sequence of the proprotein convertase PC1 is critical for its zymogen and C-terminal processing and for its cellular trafficking.","date":"1997","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9307023","citation_count":41,"is_preprint":false},{"pmid":"9148930","id":"PMC_9148930","title":"In addition to SEC11, a newly identified gene, SPC3, is essential for signal peptidase activity in the yeast endoplasmic reticulum.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9148930","citation_count":40,"is_preprint":false},{"pmid":"8070378","id":"PMC_8070378","title":"In vitro processing of proopiomelanocortin by recombinant PC1 (SPC3).","date":"1994","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8070378","citation_count":39,"is_preprint":false},{"pmid":"10340723","id":"PMC_10340723","title":"Melatonin receptors in PC3 human prostate tumor cells.","date":"1999","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/10340723","citation_count":39,"is_preprint":false},{"pmid":"22510595","id":"PMC_22510595","title":"Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells.","date":"2012","source":"Journal of radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/22510595","citation_count":38,"is_preprint":false},{"pmid":"9609127","id":"PMC_9609127","title":"Membrane glycoprotein PC-1 and insulin resistance.","date":"1998","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9609127","citation_count":37,"is_preprint":false},{"pmid":"10585559","id":"PMC_10585559","title":"PC3 overexpression affects the pattern of cell division of rat cortical precursors.","date":"2000","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/10585559","citation_count":37,"is_preprint":false},{"pmid":"7559585","id":"PMC_7559585","title":"Mutational analysis of PC1 (SPC3) in PC12 cells. 66-kDa PC1 is fully functional.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7559585","citation_count":36,"is_preprint":false},{"pmid":"27248169","id":"PMC_27248169","title":"MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27248169","citation_count":36,"is_preprint":false},{"pmid":"9528943","id":"PMC_9528943","title":"Proglucagon processing in an islet cell line: effects of PC1 overexpression and PC2 depletion.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9528943","citation_count":31,"is_preprint":false},{"pmid":"11517193","id":"PMC_11517193","title":"Coexpression of proprotein convertase SPC3 and the neuroendocrine precursor proSAAS.","date":"2001","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11517193","citation_count":29,"is_preprint":false},{"pmid":"29721191","id":"PMC_29721191","title":"MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29721191","citation_count":29,"is_preprint":false},{"pmid":"11405624","id":"PMC_11405624","title":"Partial silencing of the NEC1 gene results in early opening of anthers in Petunia hybrida.","date":"2001","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/11405624","citation_count":28,"is_preprint":false},{"pmid":"26330543","id":"PMC_26330543","title":"Molecular Consequences of Proprotein Convertase 1/3 (PC1/3) Inhibition in Macrophages for Application to Cancer Immunotherapy: A Proteomic Study.","date":"2015","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/26330543","citation_count":26,"is_preprint":false},{"pmid":"28132887","id":"PMC_28132887","title":"PC1/3 Deficiency Impacts Pro-opiomelanocortin Processing in Human Embryonic Stem Cell-Derived Hypothalamic Neurons.","date":"2017","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28132887","citation_count":25,"is_preprint":false},{"pmid":"37601320","id":"PMC_37601320","title":"Analytical performance of the FDA-cleared Parsortix® PC1 system.","date":"2023","source":"Journal of circulating biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/37601320","citation_count":25,"is_preprint":false},{"pmid":"9523585","id":"PMC_9523585","title":"Differential cleavage of provasopressin by the major molecular forms of SPC3.","date":"1998","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9523585","citation_count":25,"is_preprint":false},{"pmid":"21556577","id":"PMC_21556577","title":"Expression of activin and activin receptors in pc3 human prostatic-cancer cells.","date":"1995","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21556577","citation_count":25,"is_preprint":false},{"pmid":"24280991","id":"PMC_24280991","title":"Exome sequencing finds a novel PCSK1 mutation in a child with generalized malabsorptive diarrhea and diabetes insipidus.","date":"2013","source":"Journal of pediatric gastroenterology and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/24280991","citation_count":25,"is_preprint":false},{"pmid":"19376969","id":"PMC_19376969","title":"Functional and structural characterization of a dense core secretory granule sorting domain from the PC1/3 protease.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19376969","citation_count":25,"is_preprint":false},{"pmid":"30388220","id":"PMC_30388220","title":"c-Myc is a regulator of the PKD1 gene and PC1-induced pathogenesis.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30388220","citation_count":24,"is_preprint":false},{"pmid":"27187384","id":"PMC_27187384","title":"Effect of AQP9 Expression in Androgen-Independent Prostate Cancer Cell PC3.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27187384","citation_count":24,"is_preprint":false},{"pmid":"23383060","id":"PMC_23383060","title":"Functional consequences of a novel variant of PCSK1.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23383060","citation_count":24,"is_preprint":false},{"pmid":"11120670","id":"PMC_11120670","title":"Regulation of prohormone convertase 1 (PC1) by thyroid hormone.","date":"2001","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11120670","citation_count":24,"is_preprint":false},{"pmid":"32319174","id":"PMC_32319174","title":"Transcription factor Creb3l1 regulates the synthesis of prohormone convertase enzyme PC1/3 in endocrine cells.","date":"2020","source":"Journal of neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32319174","citation_count":23,"is_preprint":false},{"pmid":"25828575","id":"PMC_25828575","title":"Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells.","date":"2015","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/25828575","citation_count":22,"is_preprint":false},{"pmid":"21303942","id":"PMC_21303942","title":"Modulation of PC1/3 activity by self-interaction and substrate binding.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21303942","citation_count":22,"is_preprint":false},{"pmid":"26207343","id":"PMC_26207343","title":"Revisiting PC1/3 Mutants: Dominant-Negative Effect of Endoplasmic Reticulum-Retained Mutants.","date":"2015","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26207343","citation_count":21,"is_preprint":false},{"pmid":"18304460","id":"PMC_18304460","title":"Expression of nucleostemin in prostate cancer and its effect on the proliferation of PC-3 cells.","date":"2008","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18304460","citation_count":21,"is_preprint":false},{"pmid":"23056534","id":"PMC_23056534","title":"Pax6 directly down-regulates Pcsk1n expression thereby regulating PC1/3 dependent proinsulin processing.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23056534","citation_count":20,"is_preprint":false},{"pmid":"22169851","id":"PMC_22169851","title":"Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives.","date":"2011","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22169851","citation_count":19,"is_preprint":false},{"pmid":"24140494","id":"PMC_24140494","title":"Association of the rs6235 variant in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene with obesity and related traits in a Taiwanese population.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24140494","citation_count":19,"is_preprint":false},{"pmid":"32839357","id":"PMC_32839357","title":"A rice bran phytochemical, cyanidin 3-glucoside, inhibits the progression of PC3 prostate cancer cell.","date":"2020","source":"Anatomy & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32839357","citation_count":19,"is_preprint":false},{"pmid":"31023247","id":"PMC_31023247","title":"Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31023247","citation_count":19,"is_preprint":false},{"pmid":"24828610","id":"PMC_24828610","title":"Defective transport of the obesity mutant PC1/3 N222D contributes to loss of function.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24828610","citation_count":19,"is_preprint":false},{"pmid":"27483851","id":"PMC_27483851","title":"Enhanced Cytotoxicity of Biomolecules Loaded Metallic Silver Nanoparticles Against Human Liver (HepG2) and Prostate (PC3) Cancer Cell Lines.","date":"2016","source":"Journal of nanoscience and nanotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/27483851","citation_count":19,"is_preprint":false},{"pmid":"28358602","id":"PMC_28358602","title":"In Vitro Incorporation of Radioiodinated Eugenol on Adenocarcinoma Cell Lines (Caco2, MCF7, and PC3).","date":"2017","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/28358602","citation_count":19,"is_preprint":false},{"pmid":"11081197","id":"PMC_11081197","title":"Distribution and regulation of proconvertases PC1 and PC2 in human pituitary adenomas.","date":"1999","source":"Pituitary","url":"https://pubmed.ncbi.nlm.nih.gov/11081197","citation_count":18,"is_preprint":false},{"pmid":"16886623","id":"PMC_16886623","title":"Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.","date":"2006","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16886623","citation_count":18,"is_preprint":false},{"pmid":"19615363","id":"PMC_19615363","title":"Skp2 enhances polyubiquitination and degradation of TIS21/BTG2/PC3, tumor suppressor protein, at the downstream of FoxM1.","date":"2009","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19615363","citation_count":18,"is_preprint":false},{"pmid":"18941442","id":"PMC_18941442","title":"Transplantation of PC1/3-Expressing alpha-cells improves glucose handling and cold tolerance in leptin-resistant mice.","date":"2008","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18941442","citation_count":17,"is_preprint":false},{"pmid":"31974728","id":"PMC_31974728","title":"A novel mutation in the mouse Pcsk1 gene showing obesity and diabetes.","date":"2020","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/31974728","citation_count":17,"is_preprint":false},{"pmid":"12074925","id":"PMC_12074925","title":"Thioester function is conserved in SpC3, the sea urchin homologue of the complement component C3.","date":"2002","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12074925","citation_count":17,"is_preprint":false},{"pmid":"26028116","id":"PMC_26028116","title":"Inhibition of Transient Receptor Potential Melastain 7 Enhances Apoptosis Induced by TRAIL in PC-3 cells.","date":"2015","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/26028116","citation_count":17,"is_preprint":false},{"pmid":"29301501","id":"PMC_29301501","title":"Inhibition of neddylation facilitates cell migration through enhanced phosphorylation of caveolin-1 in PC3 and U373MG cells.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29301501","citation_count":17,"is_preprint":false},{"pmid":"33684465","id":"PMC_33684465","title":"Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells.","date":"2021","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/33684465","citation_count":17,"is_preprint":false},{"pmid":"7840657","id":"PMC_7840657","title":"In vitro processing of anthrax toxin protective antigen by recombinant PC1 (SPC3) and bovine intermediate lobe secretory vesicle membranes.","date":"1995","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/7840657","citation_count":15,"is_preprint":false},{"pmid":"21496226","id":"PMC_21496226","title":"Differential disease resistance response in the barley necrotic mutant nec1.","date":"2011","source":"BMC plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/21496226","citation_count":15,"is_preprint":false},{"pmid":"32841893","id":"PMC_32841893","title":"Induction of proliferative and mutagenic activity by benzo(a)pyrene in PC-3 cells via JAK2/STAT3 pathway.","date":"2020","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/32841893","citation_count":15,"is_preprint":false},{"pmid":"17645548","id":"PMC_17645548","title":"PC1/3, PC2 and PC5/6A are targeted to dense core secretory granules by a common mechanism.","date":"2007","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/17645548","citation_count":15,"is_preprint":false},{"pmid":"36063535","id":"PMC_36063535","title":"Saffron extract feed improves the antioxidant status of laying hens and the inhibitory effect on cancer cells (PC3 and MCF7) Growth.","date":"2022","source":"Veterinary medicine and science","url":"https://pubmed.ncbi.nlm.nih.gov/36063535","citation_count":14,"is_preprint":false},{"pmid":"29610180","id":"PMC_29610180","title":"Blue Diaper Syndrome and PCSK1 Mutations.","date":"2018","source":"Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/29610180","citation_count":14,"is_preprint":false},{"pmid":"33138149","id":"PMC_33138149","title":"Simplicilones A and B Isolated from the Endophytic Fungus Simplicillium subtropicum SPC3.","date":"2020","source":"Antibiotics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33138149","citation_count":14,"is_preprint":false},{"pmid":"26778167","id":"PMC_26778167","title":"The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26778167","citation_count":14,"is_preprint":false},{"pmid":"16019130","id":"PMC_16019130","title":"Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16019130","citation_count":14,"is_preprint":false},{"pmid":"9302374","id":"PMC_9302374","title":"Expression of the putative inhibitor of the insulin receptor tyrosine kinase PC-1 in dermal fibroblasts from patients with syndromes of severe insulin resistance.","date":"1997","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9302374","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50725,"output_tokens":6509,"usd":0.124905},"stage2":{"model":"claude-opus-4-6","input_tokens":10137,"output_tokens":4578,"usd":0.247702},"total_usd":0.372607,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"PC1/3 is a calcium-dependent serine proteinase with optimal activity at pH 5.5–6.5 that undergoes autocatalytic cleavage of its N-terminal prosegment (at RSKR motif, residues 80–83) early in biosynthesis, and cleaves proenkephalin to yield peptide B-sized fragment; specificity studies show preference for arginine 4 amino acids N-terminal to the cleavage site.\",\n      \"method\": \"Purification of recombinant mouse PC1 from CHO conditioned medium, fluorogenic substrate assays, in vitro proenkephalin cleavage, inhibitor profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified recombinant enzyme, multiple orthogonal assays\",\n      \"pmids\": [\"8449925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"PC1/3 undergoes autocatalytic C-terminal truncation from 87 kDa to 74/66 kDa forms in vitro; the truncated forms have narrower pH optimum (5.0–5.5), are more enzymatically active but less stable, and show altered sensitivity to protease inhibitors compared with the 87-kDa form.\",\n      \"method\": \"In vitro spontaneous conversion assay, limited proteolysis, purification, fluorogenic substrate kinetics, inhibitor profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with multiple biochemical readouts\",\n      \"pmids\": [\"8034588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Recombinant PC1 cleaves POMC in vitro at all paired-basic residue sites (except Lys-Arg and Lys-Lys in beta-lipotropin/beta-endorphin), generating ACTH intermediates, ACTH, joining peptide, 16-kDa N-POMC, N-POMC-(1-74), and beta-lipotropin, with a pH optimum of 6.0.\",\n      \"method\": \"In vitro processing of mouse POMC with partially purified recombinant rat PC1 from stably transfected L-cells, peptide product identification\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro reconstitution with defined substrate and product mapping\",\n      \"pmids\": [\"8070378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The C-terminal truncation site of PC1 is at Arg590-Arg591; mutation of this site prevents processing from 87 kDa form, while a truncated mutant ending at this site is correctly routed to secretory granules and processes proneurotensin efficiently, indicating the C-terminal extension is not required for granule sorting but regulates enzyme activity.\",\n      \"method\": \"Site-directed mutagenesis of PC1 expressed in PC12 cells, proneurotensin processing assay, secretory pathway analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with defined substrate processing readout and subcellular localization\",\n      \"pmids\": [\"7559585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The RRGDL motif in the P-domain of PC1 is critical for zymogen processing in the ER, C-terminal autocatalytic processing to the 66-kDa form in secretory granules, and proper trafficking to granules; RRGDL mutations cause ER retention/degradation, mis-sorting to the constitutive pathway, and impaired POMC processing.\",\n      \"method\": \"Site-directed mutagenesis (ARGDL, RAGDL, RRGEL variants), vaccinia-virus expression in BSC40/PC12/GH4C1 cells, pulse-chase analysis, immunocytochemistry, alpha1-PDX inhibitor co-expression\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with multiple cell-biological and biochemical assays\",\n      \"pmids\": [\"9307023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PC1/SPC3 cleaves provasopressin at both vasopressin-neurophysin and neurophysin-glycopeptide junctions; cleavage specificity differs between the 86-kDa (unprocessed C-terminus) and 64-kDa (C-terminally truncated) forms: 86-kDa form cleaves only at the neurophysin-glycopeptide site, while 64-kDa forms cleave at both sites, demonstrating that the C-terminus alters cleavage specificity.\",\n      \"method\": \"In vitro processing of radiolabeled provasopressin and prooxytocin with different recombinant SPC3 forms, including 64-kDa SPC3-T truncation construct\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with multiple enzyme forms and defined substrates\",\n      \"pmids\": [\"9523585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PC3/PC1 (86 and 64 kDa forms) associates with lipid rafts in secretory granule membranes; a 64-kDa form (PC3-TM) contains a transmembrane domain (residues 619–638) anchoring it to lipid rafts with an ~115-residue cytoplasmic tail; the transmembrane domain alone is sufficient to target a heterologous protein (IL2 receptor Tac ectodomain) to secretory granules.\",\n      \"method\": \"TX-100 detergent resistance, sucrose gradient flotation, cholesterol depletion, protease protection, immunolabeling, biotinylation of intact granules, 2D gel electrophoresis, IL2R-Tac chimera targeting assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical and cell-biological methods in single study\",\n      \"pmids\": [\"12950171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The extreme C-terminal sorting domain of PC1/3 (residues 711–753) adopts two alpha-helices (722–728 and 738–750) by NMR; the second helix is necessary and sufficient to target a constitutively secreted protein to dense core secretory granules, and L745 anchors a hydrophobic patch critical for sorting; calcium binding by this helix promotes aggregation via the hydrophobic patch.\",\n      \"method\": \"NMR structure determination of PC1/3(711-753) in micelles, deletion/mutagenesis functional targeting assays, calcium-binding aggregation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure combined with mutagenesis and functional targeting assays\",\n      \"pmids\": [\"19376969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PC1/3, PC2, and PC5/6A are targeted to dense core secretory granules by a common mechanism requiring a C-terminal alpha-helix with clustered hydrophobic residues; predicted alpha-helix in PC5/6A C-terminus redirects a constitutively secreted protein to granules in AtT-20 cells.\",\n      \"method\": \"C-terminal fusion protein targeting assays in AtT-20 cells, alpha-helix prediction, comparison of PC1/3, PC2, PC5/6A sorting domains\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-based functional targeting assays with multiple PC family members\",\n      \"pmids\": [\"17645548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"PC1 (but not furin or PC2) efficiently cleaves prosomatostatin at the dibasic Arg-Lys site to produce somatostatin-14 in heterologous cell expression; furin mediates monobasic cleavage in the constitutive pathway, while PC1 is required for dibasic cleavage in the regulated pathway.\",\n      \"method\": \"Transient transfection of PC1, PC2 in COS-7 and AtT-20 cells; PSS processing product analysis; correlation with endogenous convertase expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — heterologous expression with defined substrate and product characterization, multiple cell types\",\n      \"pmids\": [\"8095501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Overexpression of PC1 in islet-derived InR1-G9 cells drives proglucagon processing toward glicentin, oxyntomodulin, and GLP-2 (intestinal-type products), but does not increase GLP-1(7-36NH2); antisense depletion of PC2 eliminates glicentin but does not alter glucagon, establishing distinct roles for PC1 and PC2 in proglucagon processing.\",\n      \"method\": \"Stable transfection of PC1 or antisense PC2 in InR1-G9 cells, HPLC and RIA of proglucagon-derived peptides\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — stable cell lines, multiple biochemical readouts, orthogonal gain- and loss-of-function\",\n      \"pmids\": [\"9528943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The N221D variant of PC1/3 (encoded by rs6232) has significantly impaired catalytic activity in vitro; in N222D knock-in mice, the mutation causes obesity, abnormal proinsulin processing, reduced hypothalamic alpha-MSH, and impaired autocatalytic activation of mature PC1, phenocopying human PC1 deficiency.\",\n      \"method\": \"Functional analysis of N221D mutant in vitro; N222D mouse knock-in model with metabolic phenotyping, proinsulin processing assay\",\n      \"journal\": \"Nature genetics / Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro catalytic assay plus in vivo mouse model with multiple endocrine phenotypes\",\n      \"pmids\": [\"18604207\", \"16644867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The PC1/3 N222D mutation causes ER retention and accelerated proteasomal degradation of the mutant protein; coimmunoprecipitation shows N222D protein interacts with wild-type PC1/3 and exerts a modest dominant-negative effect on intracellular retention of WT enzyme.\",\n      \"method\": \"Pulse-chase immunoprecipitation, metabolic labeling, immunohistochemistry, ubiquitin-proteasome inhibitor experiments, co-IP in transfected cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal cell-biology methods with mechanistic follow-up\",\n      \"pmids\": [\"24828610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ER-retained PC1/3 mutants (G209R and G593R) induce ER stress markers and exert dominant-negative blockade of wild-type PC1/3 prodomain cleavage and expression, facilitating entry of WT protein into a proteasomal degradation pathway.\",\n      \"method\": \"Expression of mutants alongside WT PC1/3 in transfected cells, ER stress marker assays, Western blot analysis of WT PC1/3 processing\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-based co-expression with multiple biochemical readouts\",\n      \"pmids\": [\"26207343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PC1/3 exists as multiple ionic forms including inactive aggregates and stable oligomers; the most active form is a probable homodimer of 87-kDa PC1/3; enzyme activity of 87-kDa oligomers exhibits partial latency that is relieved by dilution or by preincubation with fluorogenic substrate or peptides containing paired basic residues, suggesting regulation by self-interaction and substrate binding.\",\n      \"method\": \"Ion exchange chromatography, 2D gel electrophoresis, gel filtration, cross-linking, fluorogenic activity assays with and without substrate peptides\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biophysical and enzymatic methods\",\n      \"pmids\": [\"21303942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"proSAAS (encoded by Pcsk1n) is a potent and specific inhibitor of PC1/3 (SPC3) and is co-expressed with SPC3 in nearly all neuroendocrine cells and neurons throughout the brain and peripheral endocrine tissues, supporting an in vivo inhibitory role.\",\n      \"method\": \"In situ hybridization histochemistry double-labeling in rat CNS and peripheral tissues; correlation with prior in vitro inhibition data\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — co-localization study supporting in vitro inhibition data from prior work\",\n      \"pmids\": [\"11517193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Pax6 transcription factor directly binds the Pcsk1n (proSAAS) promoter and down-regulates its expression; Pax6 deficiency elevates proSAAS levels, which inhibits PC1/3 C-terminal cleavage and reduces PC1/3 activity, thereby impairing proinsulin processing.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation, EMSA, Pcsk1n RNAi in MIN6 cells, PC1/3 activity assay, proinsulin processing assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including ChIP, EMSA, reporter, functional rescue\",\n      \"pmids\": [\"23056534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Thyroid hormone receptor alpha1 (TRalpha1) negatively regulates PC1 promoter activity by binding to novel TRE-like sequences located at −10 to +19 bp relative to the transcription start site, both as monomer/homodimer and as TRalpha1/RXRbeta heterodimer/multimer.\",\n      \"method\": \"5' deletion constructs of hPC1 promoter transfected into GH3 cells, EMSA with purified TRalpha1 and RXRbeta, point mutations of putative TREs\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter deletion analysis, purified protein EMSA, mutagenesis\",\n      \"pmids\": [\"11120670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Transcription factor Creb3l1 directly binds a G-box motif in the Pcsk1 promoter and transcriptionally activates PC1/3 expression; viral Creb3l1 over-expression in hypothalamic supraoptic nuclei increases Pcsk1, while knockdown reduces it; in AtT20 cells, Creb3l1 knockdown reduces Pcsk1 expression.\",\n      \"method\": \"RNA-seq of Creb3l1 KD AtT20 cells, promoter-binding assay, viral vector over-expression/knockdown in vivo and in vitro\",\n      \"journal\": \"Journal of neuroendocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple gain- and loss-of-function approaches with direct promoter binding evidence\",\n      \"pmids\": [\"32319174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Recombinant PC1 cleaves anthrax toxin protective antigen (PA83) at the tetrabasic RKKR167 site to generate PA63 and PA20, with pH optimum 6.0 and calcium dependence; PC1 prefers substrates with basic residues at −1 and −4 positions; bovine intermediate lobe secretory vesicle membrane PC1 (immunodepleted) also cleaves PA, confirming in vivo relevance.\",\n      \"method\": \"In vitro cleavage of PA with recombinant PC1 from L-cells, N-terminal sequencing of products, site-directed mutagenesis of PA cleavage site, immunodepletion with PC1/PC2 antisera, cellular toxicity assay\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with N-terminal sequencing and mutagenesis of substrate\",\n      \"pmids\": [\"7840657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In macrophages, PC1/3 inhibition (knockdown or genetic KO) promotes an M1 pro-inflammatory phenotype characterized by filopodial extensions, TLR4 MyD88-dependent signaling, increased calcium entry, and secretion of pro-inflammatory factors recruiting cytotoxic T cells.\",\n      \"method\": \"PC1/3 siRNA knockdown in NR8383 macrophages, validation in PC1/3-deficient mouse macrophages, proteomic analysis of secretomes and intracellular proteins\",\n      \"journal\": \"Molecular & cellular proteomics : MCP\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two model systems (cell and mouse KO) with proteomics, but mechanistic depth limited\",\n      \"pmids\": [\"26330543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PC1/3 co-localizes with and controls TLR9 trafficking in macrophages; PC1/3 knockdown causes TLR9 clustering in multivesicular bodies (Rab7+), dampens anti-inflammatory STAT3 signaling, and promotes pro-inflammatory NF-kB signaling and cytokine secretion.\",\n      \"method\": \"PC1/3 knockdown in NR8383 macrophages and PC1/3 KO mice macrophages, co-localization imaging with TLR9/Rab7 markers, STAT3/NF-kB pathway readouts, cytokine ELISA\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two model systems with defined pathway readouts; co-localization supports mechanistic interpretation\",\n      \"pmids\": [\"26778167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A heterozygous nonsense PCSK1 mutation (p.Arg80*) produces a truncated propeptide fragment that inhibits PCSK1 enzyme activity in vitro; this inhibition does not involve strong physical interaction with the mature enzyme, yet is sufficient to cause dominantly inherited obesity in a three-generation family.\",\n      \"method\": \"In vitro functional analysis of truncated propeptide, co-segregation analysis in family, activity assays\",\n      \"journal\": \"International journal of obesity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro enzyme inhibition assay with genetic co-segregation support\",\n      \"pmids\": [\"24890885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In Prader-Willi syndrome, loss of SNORD116 leads to reduced NHLH2 and PC1/3 (PCSK1) expression in iPSC-derived neurons and mouse hypothalamus; Snord116 paternal KO mice show in vivo defects in prohormone processing of proinsulin, pro-GHRH, and proghrelin, establishing PC1/3 as the mechanistic link between SNORD116 deficiency and PWS endocrinopathy.\",\n      \"method\": \"iPSC-derived neurons from PWS patients, Snord116p-/m+ mice, in vivo prohormone processing assays (proinsulin, pro-GHRH, proghrelin), PC1/3 protein quantification in islet/hypothalamus/stomach\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human iPSC-derived neurons plus mouse model with direct prohormone processing readouts\",\n      \"pmids\": [\"27941249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GLP-1 receptor agonist liraglutide increases PC1/3 (PCSK1) mRNA expression in a subset of pancreatic alpha cells in a beta-cell GLP-1R-dependent manner in mice, promoting a beta-cell-like gene expression signature and increased bihormonal insulin+glucagon+ cells.\",\n      \"method\": \"Mouse GLP-1R beta-cell-specific KO models, human islet scRNA-seq (DART-Seq), IHC for bihormonal cells\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse model plus human islet validation, but mechanism upstream of PC1/3 induction is indirect\",\n      \"pmids\": [\"33554958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CRISPR-Cas9 and shRNA-mediated PCSK1 deficiency in hESC-derived hypothalamic neurons results in increased unprocessed POMC, decreased ratios of processed POMC peptides (ACTH, alpha-MSH), increased melanocortin receptor expression, increased PRCP expression, and reduced ACTH secretion, phenocopying PC1/3-null mice and human patients.\",\n      \"method\": \"CRISPR-Cas9 KO and shRNA KD of PCSK1 in hESC-derived hypothalamic neurons, POMC peptide processing analysis\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent KO/KD approaches in human-derived neurons with defined molecular phenotype\",\n      \"pmids\": [\"28132887\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PCSK1-encoded prohormone convertase 1/3 (PC1/3) is a calcium-dependent serine endoprotease of the subtilisin family that undergoes autocatalytic propeptide removal in the ER and C-terminal truncation in secretory granules to generate progressively more active forms (87→74/66 kDa); it cleaves prohormone substrates (POMC, proinsulin, proglucagon, proenkephalin, prosomatostatin, provasopressin, proghrelin, pro-GHRH) at paired basic residues with pH optimum ~5.5–6.5; targeting to dense core secretory granules is mediated by a C-terminal alpha-helical sorting domain (residues 738–750) containing a critical hydrophobic patch centered on L745 that binds calcium and promotes membrane aggregation; enzyme activity is regulated by self-oligomerization, substrate-induced stabilization, the endogenous inhibitor proSAAS/PCSK1N, and transcriptional control by thyroid hormone receptors and Creb3l1; ER-retained missense mutants cause dominant-negative suppression of wild-type PC1/3 maturation and activate the unfolded protein response, while obesity-associated variants (N221D) cause ER retention and proteasomal degradation with consequent impairment of prohormone processing; in macrophages, PC1/3 additionally controls TLR9 endosomal trafficking and inflammatory signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PCSK1 encodes prohormone convertase 1/3 (PC1/3), a calcium-dependent subtilisin-like serine endoprotease that is the principal processing enzyme for neuroendocrine prohormones in the regulated secretory pathway. PC1/3 undergoes sequential autocatalytic activation—N-terminal propeptide removal in the ER followed by C-terminal truncation (87→74→66 kDa) in secretory granules—yielding progressively more active forms with shifted pH optima and altered substrate specificity, and cleaves proinsulin, POMC, proglucagon, prosomatostatin, provasopressin, proghrelin, and pro-GHRH at paired basic residues [PMID:8449925, PMID:8034588, PMID:8070378, PMID:9528943, PMID:27941249]. Targeting to dense-core secretory granules depends on a C-terminal α-helical sorting domain (residues 738–750) whose hydrophobic patch (centered on L745) promotes calcium-dependent membrane aggregation, while enzyme activity is further regulated by homodimerization, substrate-induced delatentization, and the endogenous inhibitor proSAAS [PMID:19376969, PMID:21303942, PMID:11517193]. Loss-of-function and dominant-negative PCSK1 mutations—including ER-retained missense variants that activate the unfolded protein response and recruit wild-type PC1/3 into proteasomal degradation—cause monogenic obesity with impaired prohormone processing, and reduced PCSK1 expression downstream of SNORD116 loss mechanistically links Prader–Willi syndrome to its characteristic endocrinopathy [PMID:18604207, PMID:24828610, PMID:26207343, PMID:24890885, PMID:27941249].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing PC1/3 as a calcium-dependent, acidic-pH-optimum endoprotease with paired-basic-residue specificity resolved how prohormones are cleaved within the regulated secretory pathway.\",\n      \"evidence\": \"Purification of recombinant mouse PC1 from CHO cells with fluorogenic substrate kinetics, proenkephalin cleavage, and inhibitor profiling; parallel cell-based prosomatostatin processing assays\",\n      \"pmids\": [\"8449925\", \"8095501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of the catalytic domain not yet determined\", \"Full kinetic parameters for diverse prohormone substrates not systematically measured\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstrating that PC1/3 undergoes autocatalytic C-terminal truncation generating 74/66-kDa forms with higher activity and narrower pH optima revealed a built-in activation cascade that tunes enzyme function along the secretory pathway.\",\n      \"evidence\": \"In vitro spontaneous conversion assays, kinetics of multiple PC1 forms, and in vitro POMC processing with product mapping\",\n      \"pmids\": [\"8034588\", \"8070378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular compartment where each truncation step occurs was inferred but not directly visualized\", \"Structural basis for activity change upon truncation unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Mapping the C-terminal truncation site to Arg590–Arg591 and showing that a truncated construct still sorts to secretory granules separated the enzyme-activation role of the C-terminus from its granule-targeting function.\",\n      \"evidence\": \"Site-directed mutagenesis in PC12 cells with proneurotensin processing and subcellular localization readouts\",\n      \"pmids\": [\"7559585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sorting determinant downstream of residue 591 not yet mapped\", \"Protease responsible for C-terminal cleavage in vivo not identified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying the P-domain RRGDL motif as essential for ER zymogen processing, granule-compartment truncation, and correct trafficking established a single structural element governing multiple maturation checkpoints.\",\n      \"evidence\": \"Mutagenesis of RRGDL in BSC40/PC12/GH4C1 cells with pulse-chase, immunocytochemistry, and POMC processing assays\",\n      \"pmids\": [\"9307023\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural role of RRGDL in folding versus direct sorting interaction not resolved\", \"Whether P-domain mutations affect calcium binding was not tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showing that the 86-kDa and 64-kDa PC1/3 forms have different cleavage-site preferences on provasopressin demonstrated that C-terminal truncation is not merely activating but also specificity-altering, explaining tissue-specific prohormone processing patterns.\",\n      \"evidence\": \"In vitro processing of radiolabeled provasopressin with defined recombinant SPC3 forms\",\n      \"pmids\": [\"9523585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which C-terminal domain allosterically restricts cleavage-site selection unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that PC1 overexpression drives intestinal-type proglucagon processing (glicentin, oxyntomodulin, GLP-2) while PC2 generates glucagon resolved the long-standing question of how tissue-specific proglucagon products arise from differential convertase expression.\",\n      \"evidence\": \"Stable PC1 transfection and antisense PC2 depletion in InR1-G9 cells with HPLC/RIA product analysis\",\n      \"pmids\": [\"9528943\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GLP-1(7-36NH2) was not increased by PC1 alone, implying additional processing steps or enzymes\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of proSAAS as a potent endogenous PC1/3 inhibitor co-expressed in neuroendocrine tissues established a physiological feedback mechanism for controlling convertase activity in vivo.\",\n      \"evidence\": \"In situ hybridization double-labeling of proSAAS and SPC3 throughout rat CNS and endocrine tissues\",\n      \"pmids\": [\"11517193\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct in vivo demonstration that proSAAS regulates PC1/3 activity (e.g., proSAAS KO phenotype) was not shown in this study\", \"Stoichiometry and kinetics of inhibition in granule lumen not measured\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that thyroid hormone receptor α1 directly represses the PCSK1 promoter via novel TRE-like elements revealed a hormonal transcriptional control layer for PC1/3 expression.\",\n      \"evidence\": \"Promoter-deletion and EMSA with purified TRα1/RXRβ in GH3 cells\",\n      \"pmids\": [\"11120670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo thyroid hormone regulation of PC1/3 protein levels and prohormone processing not demonstrated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery that a 64-kDa PC1/3 form contains a transmembrane domain (residues 619–638) anchoring it to lipid rafts in secretory granule membranes, sufficient for granule targeting of a heterologous protein, revealed an unexpected membrane-tethered convertase population.\",\n      \"evidence\": \"Detergent resistance, sucrose gradient flotation, protease protection, IL2R-Tac chimera targeting assay\",\n      \"pmids\": [\"12950171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the transmembrane form represents a physiologically significant fraction of total PC1/3 in vivo is unclear\", \"Relationship between transmembrane and soluble C-terminally truncated forms not fully resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"NMR structure of the C-terminal sorting domain (residues 711–753) pinpointed a second α-helix (738–750) with a hydrophobic patch centered on L745 as the necessary and sufficient granule-sorting signal, with calcium-dependent aggregation as the targeting mechanism.\",\n      \"evidence\": \"NMR in micelles, deletion/point mutagenesis targeting assays, calcium-binding aggregation assay\",\n      \"pmids\": [\"19376969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Membrane receptor or lipid species mediating initial helix–granule interaction not identified\", \"Sorting mechanism shared with PC2/PC5 helix not structurally compared\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linking the common obesity-associated N221D variant to impaired catalytic activity in vitro and demonstrating that N222D knock-in mice phenocopy human PC1/3 deficiency (obesity, abnormal proinsulin processing, reduced α-MSH) provided the first direct genetic evidence that partial PC1/3 loss causes metabolic disease.\",\n      \"evidence\": \"In vitro catalytic assays of N221D; N222D knock-in mouse metabolic phenotyping and proinsulin processing\",\n      \"pmids\": [\"18604207\", \"16644867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the variant affects folding, ER exit, or catalysis per se was not fully dissected at this stage\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that 87-kDa PC1/3 forms latent oligomers whose activity is relieved by dilution or substrate peptides uncovered a self-regulatory mechanism whereby enzyme concentration and substrate availability gate convertase output.\",\n      \"evidence\": \"Ion exchange chromatography, gel filtration, cross-linking, and fluorogenic activity assays with substrate peptides\",\n      \"pmids\": [\"21303942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oligomer interface not structurally mapped\", \"In vivo relevance of concentration-dependent latency not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing that the N222D mutant undergoes ER retention and proteasomal degradation and exerts a dominant-negative effect on wild-type PC1/3 maturation via co-immunoprecipitable interaction explained how heterozygous missense variants cause haploinsufficiency-exceeding disease severity.\",\n      \"evidence\": \"Pulse-chase, metabolic labeling, proteasome-inhibitor rescue, co-IP in transfected cells\",\n      \"pmids\": [\"24828610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER-associated degradation is ERAD-L or ERAD-C pathway not specified\", \"Chaperone partners mediating retention not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A heterozygous nonsense mutation (p.Arg80*) producing a truncated propeptide that inhibits PC1/3 in trans established propeptide-mediated dominant-negative inhibition as a distinct pathogenic mechanism for monogenic obesity.\",\n      \"evidence\": \"In vitro inhibition assays of truncated propeptide; co-segregation in a three-generation family\",\n      \"pmids\": [\"24890885\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physical interaction between truncated propeptide and mature enzyme was not detected, leaving mechanism of inhibition unclear\", \"Only one family studied\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that additional ER-retained PC1/3 mutants (G209R, G593R) induce the unfolded protein response and block wild-type prodomain cleavage generalized the dominant-negative/ER-stress mechanism beyond N221D to a class of pathogenic variants.\",\n      \"evidence\": \"Co-expression of mutant and WT PC1/3 with ER stress marker assays and Western blot\",\n      \"pmids\": [\"26207343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether UPR activation contributes to disease phenotype beyond PC1/3 loss was not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Establishing that SNORD116 loss reduces NHLH2 and PC1/3 expression in iPSC-derived neurons and that Snord116-KO mice have defective prohormone processing identified PC1/3 deficiency as the mechanistic bridge between SNORD116 deletion and Prader–Willi syndrome endocrinopathy.\",\n      \"evidence\": \"PWS patient iPSC-derived neurons, Snord116p−/m+ mice, in vivo prohormone processing of proinsulin/pro-GHRH/proghrelin\",\n      \"pmids\": [\"27941249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mechanism by which SNORD116 snoRNA regulates NHLH2/PCSK1 mRNA (splicing, stability, translation) not elucidated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealing that PC1/3 controls TLR9 endosomal trafficking and inflammatory polarization in macrophages expanded the enzyme's role beyond neuroendocrine prohormone processing to innate immune regulation.\",\n      \"evidence\": \"PC1/3 knockdown in NR8383 macrophages and KO mouse macrophages with TLR9/Rab7 co-localization, STAT3/NF-κB pathway readouts, secretome proteomics\",\n      \"pmids\": [\"26778167\", \"26330543\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PC1/3 substrate in macrophages that mediates TLR9 trafficking not identified\", \"Whether catalytic activity or a non-enzymatic function is required was not determined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"CRISPR and shRNA ablation of PCSK1 in human ESC-derived hypothalamic neurons recapitulated impaired POMC processing with reduced ACTH/α-MSH secretion, validating the enzyme's non-redundant role in a human neuronal context.\",\n      \"evidence\": \"PCSK1 KO/KD in hESC-derived hypothalamic neurons with POMC peptide quantification\",\n      \"pmids\": [\"28132887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compensation by other convertases (PC2, furin) in human neurons not systematically assessed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of Creb3l1 as a direct transcriptional activator binding the Pcsk1 promoter G-box added a second transcription factor (beyond TRα1) to the regulatory circuit controlling PC1/3 expression in hypothalamic neurons.\",\n      \"evidence\": \"RNA-seq, promoter-binding assay, viral Creb3l1 overexpression/knockdown in vivo (supraoptic nucleus) and in AtT20 cells\",\n      \"pmids\": [\"32319174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological stimuli that activate Creb3l1 upstream of Pcsk1 not defined\", \"Whether Creb3l1 regulation extends beyond hypothalamic neurons not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the structural basis for substrate selectivity and C-terminal allosteric regulation, the identity of PC1/3 substrates in macrophages and other non-neuroendocrine cells, the mechanism by which SNORD116 controls PCSK1 expression, and whether dominant-negative ER-stress effects of pathogenic variants contribute to disease beyond simple loss of enzyme activity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution full-length structure of PC1/3\", \"Macrophage substrate identity unknown\", \"SNORD116–PCSK1 regulatory mechanism undefined\", \"In vivo contribution of UPR activation to disease pathogenesis untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 3, 5, 9, 10, 11, 14, 19, 22, 25]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3, 6, 7, 8]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4, 12, 13]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0392499\", \"supporting_discovery_ids\": [0, 1, 2, 3, 5, 9, 10, 11, 25]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 2, 3, 5, 9, 10, 11, 25]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [6, 7, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [20, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [20, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PCSK1N\",\n      \"POMC\",\n      \"TLR9\",\n      \"CREB3L1\",\n      \"PAX6\",\n      \"THRA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}